Drug Profile
Research programme: Rho signalling pathway inhibitors - BioAxone BioSciences
Alternative Names: BA 1016; BA 1037; BA 2017; BA 285; BA-1076; BA-207; BA-215; BA-240; Rhostatin™; ROCK2 inhibitors - BioAxone BioSciencesLatest Information Update: 13 Jul 2018
Price :
$50
*
At a glance
- Originator BioAxone Therapeutic
- Developer BioAxone Biosciences; BioAxone Therapeutic
- Class Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Neuroprotectants; Small molecules
- Mechanism of Action Rho GTP-binding protein inhibitors; Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Glaucoma
- Discontinued Cancer; Cancer metastases; Cardiovascular disorders; CNS trauma; Optic nerve disorders; Retinal disorders